Bridgebio Pharma Inc (BBIO) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Bridgebio Pharma Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Bridgebio Pharma Inc 's ROA in the second quarter of 2026?
Bridgebio Pharma Inc recorded a cumulative net loss of $-702 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -62.15%.
However, within the Healthcare sector 626 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4094, from total ROA ranking in the first quarter of 2026 at 4844.
BridgeBio Pharma: Navigating the Dichotomy of Rising Demand and Pertinent Financial LossesIn the realm of biotechnology, where innovation is as commendable as it is hazardous, BridgeBio Pharma Inc. stands at a crossroads. The Palo Alto-based company has recently reported remarkable strides in its portfolio, particularly concerning treatments for genetic diseases such as transthyretin amyloid cardiomyopathy (ATTR-CM) and achondroplasia. However, amidst this commercial progress, the company grapples with staggering financial losses that raise questions about its long-term viability.BridgeBio announced a cumulative net loss of $446 million for the 12 months ending the third quarter of 2024. This dismal figure translates to a piercing negative return on assets (ROA) of -63.06%. Such financial metrics are alarming for stakeholders, who must weigh the company’s promising breakthroughs against its troubling fiscal sustainability.
In a notable advancement within the intersection of finance and biotechnology, BridgeBio Pharma has announced the publication of a compelling case study exploring the implications of portfolio theory on biomedical innovation. This scholarly work appears in the esteemed Journal of Portfolio Management and stands as a testament to the innovative approaches BridgeBio employs in tackling some of today s most pressing health challenges.The case study, co-authored by members of BridgeBio’s senior management team and Andrew W. Lo, Ph.D. a prominent MIT professor and co-founder of BridgeBio delves into how strategic financial frameworks can be effectively applied within the biomedical sector to enhance research and development outcomes. At its core, the study demonstrates the relevance of portfolio theory, traditionally utilized in finance to manage risk and optimize returns, in fostering innovation in drug development processes.
In a recent press release, BridgeBio Pharma, a prominent biopharmaceutical company specializing in genetic diseases and cancers, announced the approval of equity grants for 24 new employees. These grants, in the form of restricted stock units, amount to a total of 97,557 shares of the company s common stock. Notably, the vesting of these shares will be staggered over time, contingent upon the employees continued employment with the company. These inducement grants were made in accordance with BridgeBio s Amended and Restated 2019 Inducement Equity Plan (the Plan). This development follows BridgeBio Pharma s financial performance for the twelve months ending in the third quarter of 2023. During this period, the company recorded a cumulative net loss of $-623 million, resulting in a negative return on assets (ROA) of -105.01%. These figures indicate the financial challenges faced by BridgeBio in a fiercely competitive market. Moreover, within the Healthcare sector, 871 other companies exhibited higher returns on assets, underscoring the need for BridgeBio Pharma to strengthen its financial position and improve its overall market standing.
BridgeBio Accelerates Oncology Pipeline with $200M Financing BridgeBio Pharma, a leading biopharmaceutical company focused on genetic diseases and cancers, has announced the completion of a $200M private financing for its subsidiary, BridgeBio Oncology Therapeutics (BBOT). This strategic move aims to expedite the development of BridgeBio s precision oncology pipeline and further advance its mission to deliver innovative treatments for cancer patients. The oversubscribed financing round was led by Cormorant Asset Management and co-led by Omega Funds, with participation from renowned investors including Deerfield Management, GV (Google Ventures), EcoR1 Capital, and Wellington Management, among others. The strong support from these investors underscores the promising potential of BridgeBio s oncology portfolio and its commitment to revolutionizing cancer therapeutics.
Facts: On April 5, 2024, the compensation committee of BridgeBio s board of directors approved equity grants to 19 new employees in restricted stock units for a total of 93,088 shares of the company s common stock. The vesting of these shares will occur in stages, with one-fourth of the shares vesting on May 16, 2025, and the remaining shares vesting on a quarterly basis thereafter, subject to each employee s continued employment with the company. These inducement grants were made under BridgeBio s Amended and Restated 2019 Inducement Equity Plan. This plan allows the company to attract and retain talented individuals by offering them an opportunity to become shareholders in the company.
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock - A Strategic Move to Boost Genetic Disease and Cancer Research PALO ALTO, Calif., March 5, 2024 - BridgeBio Pharma, Inc. (Nasdaq: BBIO), a leading commercial-stage biopharmaceutical company dedicated to genetic diseases and cancers, has recently announced the pricing details of a public offering of its common stock. This underwritten public offering consists of 8,620,690 shares at a price of $29.00 per share. BridgeBio has also granted the underwriters an option to purchase an additional 1,293,103 shares on the same terms. With an expected gross proceeds of approximately $250.0 million, this move is aimed at supporting their ongoing research and development efforts. BridgeBio Pharma has been making significant strides in its field, focusing on genetic diseases and cancer. The company s commitment to advancing treatments and therapies for these conditions has garnered attention, resulting in a 19.6% increase in their stock price over the past three months. This upward trend is a testament to the market s confidence in BridgeBio s innovative approach and potential for growth in the healthcare sector.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
